Coronary Artery Disease
FGF-1 was first explored to treat coronary artery disease, the number one cause of death in the United States. In a USA FDA Phase IIA Clinical Trial at the Hospital of the University of Cincinnati, the drug demonstrated its ability to grow new blood vessels in the hearts of patients with severe coronary artery disease. It is estimated that 16 million people suffer from Coronary Artery Disease in the United States of America. Coronary Artery Disease is currently an unmet medical need, and Zhittya Genesis Medicine believes it could obtain US FDA designation of a “Medical Breakthrough Therapy” for its drug for this indication.